Dyskinesia: What to Do about Moving Too Much

This is an archived file of a live webcast that took place on January 21, 2016.

In this webinar we discuss dyskinesia, involuntary movements that arise with levodopa use as Parkinson's progresses. Our panelists discuss the current management of dyskinesia and new therapies in development.

This event is part of the MJFF Third Thursdays Webinar series. Visit www.michaeljfox.org/webinars for more information and to view past webinars.

Title: Dyskinesia: What to Do about Moving Too Much

Duration: 1 hour
Continuing Medical Education Information for Health Care Professionals

Continuing Medical Education Information
MJFF offers Continuing Medical Education (CME) credit for practicing health care professionals for each Third Thursday Webinar. Click the link in the Resource List after viewing the webinar to take the post-test survey and receive your CME credit.

Date of Original Release: January 21, 2016
Date CME Credit No Longer Available: January 21, 2018

Learning Objectives
At the conclusion of this course, participants should be able to:

  • Define the clinical features of levodopa-induced dyskinesia.
  • Explain the potential pathogenetic mechanisms of levodopa-induced dyskinesia.
  • Discuss approaches for management of levodopa-induced dyskinesia.
  • Summarize ongoing research into anti-dyskinetic therapies.

Target Audience
This educational activity is designed for primary care physicians, family practice physicians, general medicine physicians, geriatricians, general neurologists, movement disorder specialists and any other health care practitioners who manage patients with Parkinson's disease.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Oakstone Publishing, LLC and The Michael J. Fox Foundation for Parkinson's Research. The Oakstone Publishing, LLC is accredited by the ACCME to provide continuing medical education for physicians.

Oakstone Publishing, LLC designates this enduring material for 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Oakstone Publishing, LLC has assessed conflict of interest with its faculty, authors, editors and any individuals who were in a position to control the content of this CME activity. Any identified relevant conflicts of interest were resolved for fair balance and scientific objectivity of studies utilized in this activity. Oakstone Publishing, LLC's planners, content reviewers, and editorial staff disclose no relevant commercial interests.

Christopher Bishop, PhD
Professor of Psychology
Binghamton University
No disclosures

Joseph Jankovic, MD
Professor of Neurology
Distinguished Chair in Movement Disorders
Director, Parkinson's Disease Center and Movement Disorders Clinic
Baylor College of Medicine
Research Grants: Adamas Pharmaceuticals, Inc; Allergan, Inc; Civitas/Acorda Therapeutics; Ipsen Limited; Kyowa Haako Kirin Pharma, Inc; Lundbeck Inc; Medtronic; Merz Pharmaceuticals; Omeros Corporation; Pfizer; Prothena Biosciences Inc; Psyadon Pharmaceuticals, Inc; St. Jude Medical; Teva Pharmaceutical Industries Ltd.
Advisory Role: Adamas Pharmaceuticals, Inc; Allergan, Inc; Teva Pharmaceutical Industries Ltd

Dave Iverson
No disclosures


Already Registered?

*Required Fields.

You must have Javascript and Cookies enabled to access this webcast. Click here for Help.

By registering you agree to receive email updates from
The Michael J. Fox Foundation. You can unsubscribe any time.